2 completed, 1 recruiting. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Directly Observed Therapy: new trials by email Literature Review of Directly Observed Therapy trials Research Report on Directly Observed Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a - Hepatitis C, Chronic | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 150 | 2018-02-02 | 2021-05-18 |
| Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients Cytoreductive prostatectomy or brachytherapy, ADT+second-generation antiandrogens ± chemotherapy - Metastatic Prostate Cancer, Therapy, Directly Observed | Phase 3 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 200 | 2016-01-01 | 2024-04-05 |
| Directly Observed Therapy in High Risk Populations in Newark, NJ Invirase, Norvir - Directly Observed Therapy, HIV Infections | Phase 3 | Completed | Saint Michael's Medical Center | 30 | 2004-04-01 | 2006-02-28 |
HIV Infections (1) · Hepatitis C, Chronic (1) · Prostatic Neoplasms (1)
Behavior (3) · Health Behavior (3) · Medication Adherence (3) · Patient Acceptance of Health Care (3) · Patient Compliance (3) · Treatment Adherence and Compliance (3) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2) · Infections (2) · RNA Virus Infections (2) · Urogenital Diseases (2) · Virus Diseases (2) · Chronic Disease (1) · Digestive System Diseases (1)
Brachytherapy (1) · Drug Therapy (1) · Ritonavir (1) · Saquinavir (1) · Sofosbuvir (1) · Surgical Procedures, Operative (1) · daclatasvir (1) · peginterferon alfa-2a (1)
Johns Hopkins Bloomberg School of Public Health (1) · Saint Michael's Medical Center (1) · The First Affiliated Hospital with Nanjing Medical University (1)
China (1) · India (1) · United States (1)
Jihad Slim, MD (1) · Lixin Hua, M.D. (1) · Shruti Mehta, PhD, MPH (1)
R01DA026727 (1)